Initially approached with caution by healthcare organizations, cloud computing is becoming more widely adopted in this arena. As cost savings outweighed potential data protection concerns, cloud adoption in healthcare increased during 2017. Healthcare information technology (IT) systems are expensive to implement, update and maintain. Cloud economics changes that by shifting from individual budgets to cost-sharing models enabled by private, multitenant and in some cases, public clouds. These trends are shifting in favor of increased IT spending on cloud hardware, software and networks.
The development of novel enzyme inhibitors has led to effective therapeutic options for diseases that were once considered difficult to treat. A newly updated study by BCC Research finds that approvals of new molecular entities will drive the global market for enzyme inhibitors to $179.9 billion by 2022. Enzyme inhibitors offer therapeutic options for myriad illnesses, including HCV, HIV, cancer, gastrointestinal disease, cardiovascular disease, inflammatory disorders, rheumatoid arthritis, neurological disorders (depression, Parkinson’s disease, Alzheimer’s disease) and diabetes.
The continuous glucose monitoring market, introduced nearly 20 years ago, is presently experiencing strong growth as diabetics, physicians, hospitals and clinics witness the benefits these devices can lend to the management of glucose levels. The market now includes blood glucose monitors, diabetes test strips, insulin durable and patch pumps, glucose sensors, and transmitters and receivers. The global market for continuous glucose monitoring equipment is expected to top $20.6 billion by 2022, according to a new study by BCC Research, at a five-year compound annual growth rate (CAGR) of 10.1%.